The majority of grant applications received and funded by NICHD are unsolicited, submitted by extramural investigators working within the mission of the Institute. However, when NICHD program staff identify areas of research that would benefit from stimulation or that demonstrate specific gaps in knowledge that should be highlighted, a Funding Opportunity Announcement (FOA) for a focused grant solicitation may be proposed. We use two types of FOA: the Program Announcement, with no set-aside of funds, and the Request for Applications, with a specific commitment of funds.
Concepts for proposed Requests for Applications (RFA) are reviewed during the Open Session of Council. These are the features of the process:
A Request for Applications (RFA) is proposed entitled “Molecular Mechanisms of the Metabolic Effect of Drugs Used in Children”. The proposed RFA will use the NIH Research Project (R01) grant award mechanism.
The proposed RFA will solicit innovative, multidisciplinary investigator-initiated research to identify and elucidate the molecular mechanisms of the adverse metabolic effects of diverse drug classes used in children and adolescents.
The scope of the proposed RFA will encompass research on the processes for the unexpected and unintended metabolic adverse side effects to many drug classes that children are now taking for a variety of diseases. These adverse events can have a profound impact on growth and development in childhood and extending into adulthood. Examples of high priority branch areas include:
Multiple drug classes across multiple therapeutic areas have been linked to metabolic adverse events. What is lacking is an understanding of the mechanism(s) behind why these adverse effects occur, who is at risk, and how to block and/or reverse these effects early on in treatment. The ultimate goal of this RFA is to promote revolutionary discoveries of translating basic knowledge in to the development of new, innovative, and efficacious strategies and targets for the molecular diagnosis, treatment and prevention of metabolic adverse effects of drugs used in children and adolescents.